Culprit-Lesion-Only Versus Multivessel Revascularization Using Drug-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: A Korean Acute Myocardial Infarction Registry-Based Analysis

Hyun Su Jo, MD1, Jong Seon Park, MD1, Jang Won Sohn, MD1, Joon Cheol Yoon, MD1, Chang Woo Sohn, MD1, Sang Hee Lee, MD1, Geu Ru Hong, MD1, Dong Gu Shin, MD1, Young Jo Kim, MD1, Myung Ho Jeong, MD1, Shung Chull Chae, MD1, Seung Ho Hur, MD1, Taek Jong Hong, MD1, In Whan Seong, MD1, Jei Keon Chae, MD1, Jay Young Khew, MD1, In Ho Chae, MD1, Myeong Chan Cho, MD16, Jang Ho Bae, MD10, Seung Woon Rha, MD12, Chong Jin Kim, MD13, Dong Hoon Choi, MD14, Yang Soo Jang, MD14, Jung Han Yoon, MD15, Wook Sung Chung, MD18, Ki Bae Seung, MD16, and Seung Jung Park, MD17

1Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital, Daegu, 2Department of Internal Medicine, Chonnam National University Medical School, Gwangju, 3Department of Internal Medicine, Kyungpook National University College of Medicine, Daegu, 4Department of Internal Medicine, Pusan National University School of Medicine, Busan, 5Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, 6Department of Internal Medicine, Chonbuk National University College of Medicine, Jeonju, 7Department of Internal Medicine, Jeonju Presbyterian Medical Center, Jeonju, 8Department of Internal Medicine, Seoul National University College of Medicine, Seongnam, 9Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, 10Department of Internal Medicine, Konyang University College of Medicine, Daejeon, 11Department of Internal Medicine, Korea University College of Medicine, Seoul, 12Department of Internal Medicine, Kyunghee University College of Medicine, Seoul, 13Department of Internal Medicine, Yonsei University Severans Hospital, Seoul, 14Department of Internal Medicine, Yonsei University Wonju Christian Hospital, Wonju, 15Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary’s Hospital, Seoul, 16Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ABSTRACT

Background and Objectives: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, complete revascularization (CR) for non-culprit lesions is not routinely recommended. The aim of this study was to compare the clinical outcomes of multivessel compared with infarct-related artery (IRA)-only revascularization in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI.

Subjects and Methods: From the Korean Acute Myocardial Infarction Registry (KAMIR) database, 1,094 STEMI patients with multivessel disease who underwent primary PCI with drug-eluting stents were enrolled in this study. The patients were divided into two groups: culprit-vessel-only revascularization (COR, n=827) group; multivessel revascularization, including non-IRA (MVR, n=267) group. The primary endpoint of this study included major adverse cardiac events (MACEs), such as death, myocardial infarction, or target or nontarget lesion revascularization at one year.

Results: There was no difference in clinical characteristics between the two groups. During the one-year follow-up, 102 (15.2%) patients in the COR group and 32 (14.2%) in the MVR group experienced at least one MACE (p=0.330). There were no differences between the two groups in terms of rates of death, myocardial infarction, or revascularization (2.1% vs. 2.0%, 0.7% vs. 0.8%, and 11.7% vs. 10.1%, respectively; p=0.822, 0.910, and 0.301, respectively). The MACE rate was higher in the incompletely revascularized patients than in the completely revascularized patients (15% vs. 9.5%, p=0.039), and the difference was attributable to a higher rate of nontarget vessel revascularization (8.6% vs. 1.8%, p=0.002).

Conclusion: Although multivessel angioplasty during primary PCI for STEMI did not reduce the MACE rate compared with culprit-vessel-only PCI, CR was associated with a lower rate of repeat revascularization after multivessel PCI.

KEY WORDS: Myocardial infarction; Coronary artery disease; Angioplasty.
Introduction

The incidence of acute myocardial infarction (AMI) in South Korea increased 2.6-fold from 1997 to 2007. From the Korean Acute Myocardial Infarction Registry (KAMIR) data between November 2005 and December 2007, ST-segment elevation myocardial infarction (STEMI) accounted for 60% of all AMI cases, with 52% of the STEMI patients having significant stenosis of the noninfarct-related arteries. The pathophysiologic process in AMI is not limited to a single coronary lesion but involves the whole coronary arterial tree. These patients with multivessel disease are at a higher risk of cardiogenic shock as well as in-hospital and long-term mortality than the cases of single-vessel disease. Moreover, patients with multiple complex lesions have a high incidence of recurrent acute coronary syndrome and revascularization; however, in multivessel coronary intervention in the context of AMI, there are concerns about procedure-related complications, lower success rates, and increased contrast use and nephropathy. Therefore, both the American College of Cardiology/American Heart Association (ACC/AHA) 2004 guidelines and the ACC/AHA/Society for Cardiac Angiography and Interventions 2005 guidelines have recommended that simultaneous coronary intervention for nonculprit lesions should not be performed in hemodynamically stable patients because this approach may be associated with an increased risk of adverse outcomes. Recently, due to advances in devices, antiplatelet therapy, and technology, complete revascularization (CR) can safely be accomplished, and a recent randomized trial has shown that in a contemporary homogeneous cohort of patients with STEMI and multivessel coronary artery disease (CAD) treated with primary percutaneous coronary intervention (PCI), culprit-lesion-only angioplasty was associated with the highest rate of cardiac events compared with multivessel treatment, with the patients scheduled for staged revascularization experiencing a similar rate of major adverse cardiac events (MACEs) as the patients undergoing complete simultaneous treatment of noninfarct-related artery (IRA). Therefore, the optimal management of patients with multivessel disease in this setting remains still unclear.

The aim of this study was to compare the one-year clinical outcomes between the two different strategies during primary PCI with drug-eluting stents (DES) in patients with STEMI and multivessel CAD.

Subjects and Methods

Patient population and study design
This study is based on a database collected by KAMIR. KAMIR is a prospective, multicenter, observational registry designed to examine current epidemiology, in-hospital management, and outcome of patients with AMI in South Korea in commemoration of the 50th anniversary of the Korean Circulation Society. Fifty hospitals with facilities for primary PCI participated in this study. Well-trained study coordinators collected data based on the standard protocol, and registered onto the web-based program. The ethics committee of each participating hospital approved the study protocol. The purpose and methods used to register patients in the KAMIR study have been previously described.

From the KAMIR database (14,885 patients), data of 3,791 eligible STEMI patients with multivessel CAD (defined as >70% diameter stenosis of two or more epicardial coronary arteries or their major branches by visual estimation) and who underwent primary PCI using drug-eluting stents within the period from November 2005 to November 2008 were collected.

ST-segment elevation myocardial infarction patients with prolonged (more than 30 minutes) chest pain starting less than 12 hours before hospital arrival, typical electrocardiographic findings, and a door-to-balloon time of less than 120 minutes were included (Fig. 1).

Patients with cardiogenic shock at presentation (systolic blood pressure: ≤90 mm Hg), left main coronary disease (≥50% diameter stenosis), and receiving bare-metal stents were excluded from the study. The eligible patients were divided into two groups and were further divided into two subgroups:

1) Culprit-vessel-only revascularization (COR) group: the IRA only was dilated, and the other arteries were left untreated during the primary procedure or index hospitalization.

2) Multivessel revascularization (MVR) group: revascularization of more than one vessel.

3) Complete revascularization subgroup: the IRA was opened, followed by dilatation of all other significantly narrowed arteries during the primary procedure or index hospitalization.

4) Incomplete revascularization (IR) subgroup: the IRA was successfully opened, followed by dilatation of only the significantly narrowed artery in three-vessel disease during the primary procedure or index hospitalization.

Definitions and endpoints
The diagnosis of AMI was based on clinical presentations, increased levels of cardiac biomarkers (increase in levels of creatine kinase-MB, troponin-I, or troponin-T), and 12-lead electrocardiographic findings. Among these patients, patients with an ST-segment elevation of at least 1 mm in two or more contiguous limb electrocardiographic leads or 2 mm in precordial leads were defined as STEMI patients.

The primary endpoint of the study was the incidence of MACE defined as cardiac or noncardiac death, reinfarction, and repeat coronary revascularization (target vessel or nontarget vessel PCI) at one year. As the follow-up period was counted from the date of discharge, in-hospital events (death, reinfarction) were not defined as MACE. For repeat revascular-
Multivessel Revascularization in ST-Segment Elevation Myocardial Infarction

rization, all PCIs or coronary artery bypass grafts (CABGs) occurring after the baseline procedure were included. Recurrent myocardial infarction was defined as recurrent symptoms with new electrocardiographic changes reflecting MI or increased levels of cardiac biomarkers at least twice the upper normal limit.16) Target lesion revascularization (TLR) was defined as PCI for restenosis or other complications of treated lesion segment from 5 mm proximal to 5 mm distal to the stent.17) Target vessel revascularization (TVR) was defined as repeated PCI for any segment of the entire coronary artery proximal and distal to target lesion, except for TLR.

Percutaneous coronary intervention procedures and follow-up
All patients had coronary lesions with ≥50% stenosis in ≥2 coronary arteries. Coronary arterial lesion type was determined according to the ACC/AHA classification. The diagnosis of the culprit vessel was based on coronary angiographic findings, 12-lead electrocardiogram, two-dimensional echocardiogram and noninvasive stress test, if possible. All patients received loading doses of aspirin 100-300 mg and clopidogrel 300-600 mg before PCI. A 50-70 U/kg dose of unfractionated heparin was used before or during PCI to maintain an activated clotting time of 250-300 seconds. After PCI, daily maintenance doses of aspirin 100 mg and clopidogrel 75 mg were prescribed. A glycoprotein IIb/IIIa inhibitor was used in patients with large thrombotic burden on angiography at the operator’s discretion. Clinical follow-up was performed for 12 months.

Results
Baseline characteristics
One thousand and ninety four patients with STEMI and multivessel CAD who met the inclusion criteria were included in the follow-up (Fig. 1). The mean age was 63.1±12.7 years, and 804 (73.5%) were men. The COR group included 827 (75.6%) patients, and the MVR group 267 (24.4%) patients. The CR subgroup included 182 (16.6%) patients, and the IR subgroup included 912 (83.4%) patients (Fig. 1). Table 1 and 2 show the distribution of the baseline characteristics between the two groups. The two groups were similar in terms of age, gender, risk factors, enzymatic infarct size, Thrombolysis in Myocardial Infarction (TIMI) flow grade,
and creatinine level, whereas there was a difference in the mean left ventricular ejection fraction (LVEF) (higher in the MVR group). Nitrate therapy was more frequent in the MVR group, whereas the two groups had similar proportions of other therapies.

**Cardiovascular events**

Forty-four (4.0%) patients died during index hospitalization, 31 (2.8%) from cardiac causes. Of them, 43 (5.2%) patients were in the COR group and in the IR subgroup, and 1 (0.4%) patient was in the MVR group and in the CR subgroup. The in-hospital mortality was higher in the COR group than in the MVR group (p<0.001). However, the multivariate analysis after adjusting for age, sex, Killip class, post-MI TIMI flow, systolic blood pressure, LVEF, existence or nonexistence of complications, and serum creatinine, did not show that

**Table 1. Baseline clinical characteristics**

| Variables                        | COR group (n=827) | MVR group (n=267) | p   |
|----------------------------------|-------------------|-------------------|-----|
| Age (years)                      | 63±13             | 62±12             | 0.152|
| Men, n (%)                       | 598 (72.3)        | 206 (77.2)        | 0.068|
| Hypertension, n (%)              | 400 (49.7)        | 124 (48.9)        | 0.388|
| Systolic BP (mm Hg)              | 128±40            | 128±26            | 0.929|
| Diabetes mellitus, n (%)         | 218 (26.8)        | 75 (29.2)         | 0.250|
| Hyperlipidemia, n (%)            | 57 (8.1)          | 11 (4.5)          | 0.062|
| Family history of CAD, n (%)     | 52 (7.1)          | 30 (12.1)         | 0.016|
| Prior history of CAD, n (%)      | 86 (10.4)         | 23 (8.6)          | 0.481|
| Killip class                     | 1.4±0.8           | 1.4±0.8           | 0.566|
| Door-to-balloon time (minutes)   | 73±23             | 71±21             | 0.098|
| CK-MB level (mg/dL)              | 239.9±492.7       | 201.8±192.8       | 0.469|
| Serum creatinine level (mg/dL)   | 1.2±1.2           | 1.1±1.0           | 0.577|
| Left ventricular EF (%)          | 50.1±11.6         | 53±10.6           | 0.004|
| Three-vessel disease, n (%)      | 330 (39.9)        | 110 (41.2)        | 0.380|
| Medications at discharge         |                   |                   |     |
| Aspirin                          | 766 (99.0)        | 261 (99.2)        | 0.514|
| Clopidogrel                      | 762 (98.4)        | 256 (97.3)        | 0.183|
| Statin                           | 654 (84.5)        | 230 (87.5)        | 0.142|
| ACEI                             | 529 (68.3)        | 190 (72.2)        | 0.134|
| Nitrate                          | 348 (45.0)        | 141 (53.6)        | 0.009|
| Beta-blocker                     | 585 (75.6)        | 202 (76.8)        | 0.378|
| In-hospital mortality            | 43 (5.2)          | 1 (0.4)           | <0.001|

BP: blood pressure, CAD: coronary artery disease, CK-MB: creatine kinase-myocardial band isoenzyme, EF: ejection fraction, ACEI: angiotensin-converting enzyme inhibitor, COR: culprit-vessel-only revascularization, MVR: multivessel revascularization

**Table 2. Baseline angiographic characteristics**

| Variables                        | COR group (n=825) | MVR group (n=267) | p   |
|----------------------------------|-------------------|-------------------|-----|
| Culprit artery                   |                   |                   |     |
| LAD, n (%)                       | 375 (45.5)        | 119 (44.6)        | 0.832|
| RCA, n (%)                       | 367 (44.5)        | 106 (39.7)        | 0.178|
| LCX, n (%)                       | 83 (10.1)         | 42 (15.7)         | 0.015|
| Type B2/C lesion, n (%)*         | 649 (84.9)        | 211 (81.8)        | 0.237|
| Preprocedural TIMI flow          | 0.8±1.1           | 0.9±1.2           | 0.131|
| Postprocedural TIMI flow         | 2.9±0.4           | 3.0±0.3           | 0.005|
| Stent size for target lesion (mm)| 26.0±6.4          | 26.0±6.7          | 0.937|
| Total number of stents           | 1.3±0.6           | 2.4±1.0           | 0.001|

*Based on the American College of Cardiology/American Heart Association coronary artery lesion definition. LAD: left anterior descending artery, RCA: right coronary artery, LCX: left circumflex artery, TIMI: Thrombolysis in Myocardial Infarction, COR: culprit-vessel-only revascularization, MVR: multivessel revascularization*
the culprit-only PCI was significantly associated with higher in-hospital mortality (p=0.0995) which had a significant p in the univariate analysis. Low post-TIMI flow (odds ratio: 0.191; 95% confidence interval: 0.044-0.834; p=0.028) and the existence of complications during index hospitalization (odds ratio: 21.916; 95% confidence interval: 1.145-419.361; p=0.028) were significantly associated with higher in-hospital mortality. The in-hospital mortality was also higher in the IR subgroup than in the CR subgroup (p=0.002).

The rates of complications during the procedure were similar between the two groups. All four acute CVA patients were in the COR group. One patient with acute thrombosis was in the MVR group and in the CR subgroup. Of the three reinfarction patients, two were in the COR group, and one was in the MVR group and in the CR subgroup. One case of acute renal failure was in the MVR group and in the IR subgroup. The other complications were ventricular tachycardia, ventricular fibrillation, atrial fibrillation, cardiogenic shock, multi-organ failure, bleeding, and atrioventricular block.

After a mean follow-up of 9.0±4.2 months from the date of discharge, 23 (2.4%) patients died, 14 (1.5%) from cardiac causes. Throughout the follow-up, 134 (14.4%) patients experienced at least one MACE, 102 (14.9%) in the COR group and 32 (13.0%) in the MVR group (p=0.379). Seven patients (five in the COR group and two in the MVR group) experienced reinfarction (MI) while 107 patients (82 in the COR group and 25 in the MVR group) underwent re-PCI or CABG (Table 3). The Kaplan-Meier analysis showed no significant difference between the two groups for survival free of total MACE and of all kinds of MACE (Fig. 2).

However, the Kaplan-Meier analysis showed significant differences between the two subgroups (the CR and IR subgroups) for survival free of total MACE and non-target vessel PCI (Table 4). The survival free of total MACE and non-target vessel PCI was lower in the IR subgroup (p=0.039 and 0.002, respectively) (Fig. 3). Fifteen of 85 patients in the MVR group and in the IR subgroup experienced at least one MACE. Of them, nine patients underwent non-target vessel PCI.

## Discussion

This study was designed to compare MVR with COR in patients with STEMI and multivessel CAD; it is the first study to compare MVR with COR in patients with STEMI in Asia. The main finding of the present study was that in hemodynamically stable patients with multiple coronary lesions treated by primary PCI using DES, MVR had a lower rate of in-hospital mortality and, after a mean follow-up of 9.0±4.2 months, it had better clinical outcomes in non-target vessel PCI-relat-
ed events than with the treatment of IRA alone. However, the additional treatment of non-IRA during primary PCI or index hospitalization, resulted in a similar risk of death, MI, TVR, and CABG compared with the culprit-vessel-only procedure. Revascularization of the nonIRA probably prevented myocardial ischemia, and these differences were associated with better clinical outcomes in the multivessel PCI group of the present study.

Due to the increased numbers of implanted coronary stents, multivessel PCI was prone to higher in-stent restenosis rates. However in the present study, the TLR and TVR rates were statistically similar between the two groups. The reason for the higher in-hospital mortality rates in the culprit-vessel-only group despite the absence of differences in the baseline clinical characteristics and complications is not clear. It might be associated with other factors, such as indications for PCI (elective, urgent, and emergent), presence of chronic total obstruction, and duration of procedure.

According to the current guidelines, PCI should be performed only in IRA, at least in patients without cardiogenic shock. However, data from the National Cardiovascular Data Registry showed that multivessel PCI should not be performed in even hemodynamically unstable patients. This is based on the hypothesis that single-IRA PCI has a more favorable benefit-to-risk ratio and better financial implications. Some studies suggest that the more conservative strategy of treating only the IRA could avoid the complications arising from longer procedures, such as the larger use of

Table 4. One-year MACE rate in the CR and IR subgroups

| Variables                  | CR subgroup (n=182) | IR subgroup (n=779) | p     |
|----------------------------|--------------------|---------------------|-------|
| Total MACE (%)             | 16 (9.5)           | 117 (15.0)          | 0.039 |
| Death (%)                  | 2 (1.2)            | 18 (2.3)            | 0.321 |
| Cardiac                    | 2 (1.2)            | 9 (1.2)             | 0.995 |
| Noncardiac                 | 0 (0)              | 9 (1.2)             | 0.157 |
| MI (%)                     | 1 (0.6)            | 5 (0.6)             | 0.798 |
| STEMI                      | 0 (0)              | 3 (0.4)             | 0.414 |
| NSTEMI                     | 1 (0.6)            | 2 (0.3)             | 0.485 |
| Revascularization events (%)| 13 (7.7)          | 94 (12.1)           | 0.068 |
| TVR                        | 10 (6.0)           | 24 (3.1)            | 0.156 |
| Nontarget vessel PCI       | 3 (1.8)            | 67 (8.6)            | 0.002 |
| CABG                       | 0 (0)              | 3 (0.4)             | 0.407 |

MACEs: major adverse cardiac events, MI: myocardial infarction, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, TVR: target vessel revascularization, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft, CR: complete revascularization, IR: Incomplete revascularization.

Fig. 3. A: one-year MACE-free survival in the CR and IR subgroups. B: one-year nontarget vessel percutaneous coronary intervention-free survival in the CR and IR subgroups. MACE: major adverse cardiac event, CR: complete revascularization, IR: Incomplete revascularization.
a contrast medium with a potentially increased risk of contrast-induced nephropathy (CIN), increased administration or radiation, as well as the danger of ischemia in noninfarcted myocardial regions.30,31 In recent years, with the development of new advanced devices and the use of platelet glycoprotein IIb/IIIa inhibitors, the outcome of multivessel PCI has markedly improved.32,33 Some reports have indicated that the multivessel approach is safe and cost-effective. Brener et al.24 retrospectively examined more than 100,000 patients with acute coronary syndromes, and demonstrated a similar incidence of in-hospital events between patients receiving single and multivessel treatment. Ijsselmuiden et al.50 randomly assigned 219 patients with acute coronary syndromes to culprit-only versus MVR, and they found that the multivessel approach had better outcomes by decreasing the need for further interventions. A recent randomized trial by Politi et al.52 has shown that in 214 patients with STEMI and multivessel CAD treated with primary PCI, COR angioplasty was associated with the highest rate of MACE compared with multivessel treatment, and that the patients scheduled for staged revascularization experienced a similar rate of MACE as the patients undergoing complete simultaneous treatment of non-IRA during the mean 2.5-year follow-up period. The findings in the present study were similar to those of the randomized trial by Politi et al. in which the incidence of repeat revascularization and in-hospital mortality were higher in the single-vessel strategy. As the definition of MACE and the follow-up duration in the present study were different from those in the trial discussed above, the total MACE results were different. Although the study by Kim et al.25 using the same KAMIR data focused on NSTEMI patients, the findings in the present study were also similar to those of the said study, in which the incidence of in-hospital mortality was higher in the culprit-only group, MVR reduced nonTVR, and there were no significant differences in the TLR.

Only one case of CIN was observed in the MVR group and in the IR subgroup. The rates of the other procedure-related or procedure-nonrelated complications were not different between the COR and MVR groups. Therefore, it was found that compared with the single-vessel approach, MVR is safe and is associated with a lower risk of nontarget PCI at a mean follow-up of 9.0±4.2 months. Moreover, CR is associated with a low risk of MACE. This result is attributable mainly to the lower incidence of nontarget vessel PCI in the CR subgroup compared with the COR group, and the result is mainly attributable to the nine added events of nontarget vessel PCI in 85 patients of the MVR group but of the IR subgroup. A possible explanation for the protective effect of multivessel PCI is that it allows a more complete treatment of other potentially unstable plaques. Indeed, the inflammatory reaction arising during acute coronary syndromes, and responsible for plaque instability is not limited to the culprit lesion, but involves the entire coronary tree.4)

Although simultaneous revascularization was not distinguished from staged revascularization, the results suggest that the multivessel and complete approach during primary PCI or index hospitalization is safe and is possibly less expensive than an incomplete approach, through a reduction in the probability of further unplanned procedures.

Limitations

The possible limitations of the present study were the imbalance in the number of patients in the two groups and the difference in the LVEF. The lack of data on stent thrombosis and CIN during the follow-up period also limits the comparison of safety between MVR and culprit-only revascularization. The present study was not a randomized controlled trial, and a selection bias may have existed. However, due to the absence of significant differences in the baseline characteristics in this study, propensity score matching was not needed in the present study.

Since protocol on selection did not exist, the selection of the culprit vessel under similar conditions varied among operators. In patients with multivessel PCI, simultaneous PCI could not be distinguished from staged PCI during index hospitalization. The registry has no information on this distinction. Although, the analysis was conducted by adjusting all the possible confounding factors, other factors could be associated with the clinical outcomes.

Conclusions

In-hospital mortality was higher in the culprit-vessel-only PCI group than in the multivessel angioplasty group, and was also higher in the IR subgroup than in the CR subgroup.

Although multivessel angioplasty during primary PCI with DES for STEMI did not reduce the rates of death, reinfarction, TLR, TVR, and CABG compared with culprit-vessel-only PCI at one year, CR was associated with reduced non-TVR events. This finding of the present study should be further corroborated in a randomized controlled trial, and if confirmed, it may eventually lead to the recommendation of multivessel and CR for patients with STEMI and multivessel CAD.

REFERENCES

1) Hong JS, Kang HC, Lee SH, Kim J. Long-term trend in the incidence of acute myocardial infarction in Korea: 1997-2007. Korean Circ J 2009;39:467-76.
2) Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients with STElevation versus non-ST-elevation acute myocardial infarction in Korea. Korean Circ J 2009;39:297-303.
3) Lee MG, Jeong MH, Ahn Y, et al. Impact of the metabolic syndrome on the clinical outcome of patients with acute ST-elevation myocardial infarction. J Korean Med Sci 2010;25:1456-61.
4) Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW. Multiple complex coronary plaques in patients with acute myo-
cardiac infarction. N Engl J Med 2000;343:915-22.
5) Muller DW, Topol EJ, Ellis SG, Sigmon KN, Lee K, Califf RM. Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1991;121:1042-9.
6) Parodi G, Memisha G, Valenti R, et al. Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience. Heart 2005;91:1541-4.
7) Shishibori MH, Topol EJ, Mukherjee D, et al. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. Am J Cardiol 2006;97:1585-90.
8) Ijsselmuiden AJ, Ezechiels J, Westendorp IC, et al. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. Am Heart J 2004;148:467-74.
9) Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009;150:170-7.
10) Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:E1-211.
11) Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;113:e166-286.
12) Politli L, Spura F, Rossi R, et al. A randomized trial of target-vessel versus multi-vessel revascularization in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010;96:662-7.
13) Lee KH, Jeong MH, Ahn YK, et al. Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea Acute Myocardial Infarction Registry. Int J Cardiol 2008;130:227-34.
14) Kwon TG, Bae JH, Jeong MH, et al. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. Int J Cardiol 2009;133:173-8.
15) Lee SR, Jeong MH, Ahn YK, et al. Clinical safety of drug-eluting stents in the Korea Acute Myocardial Infarction Registry. Circ J 2008;72:392-8.
16) Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
17) Cutlip DE, Windecker S, Mehran R, et al. Clinical end point in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
18) Ellis SG, Roubin GS, King SB 3rd, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-9.
19) Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2009;104:507-13.
20) Roe MT, Cura FA, Joski PS, et al. Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. Am J Cardiol 2001;88:170-3.
21) Corpus RA, House JA, Marso SP, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J 2004;148:493-500.
22) Kornowski R, Mehran R, Satler LF, et al. Procedural results and late clinical outcomes following multivessel coronary stenting. J Am Coll Cardiol 1999;33:420-6.
23) Moussa I, Reimers B, Moses J, et al. Long-term angiographic and clinical outcome of patients undergoing multivessel coronary stenting. Circulation 1997;96:3873-9.
24) Brener SJ, Milford-Beland S, Roe MT, Bhatt DL, Weintraub WS, Brindis RG. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J 2008;155:140-6.
25) Kim MC, Jeong MH, Ahn Y, et al. What is optimal revascularization strategy in patients with multivessel coronary artery disease in non-ST-elevation myocardial infarction? Multivessel or culprit-only revascularization. Int J Cardiol 2010 [Epub ahead of print].